Fig. 2From: Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysisChange from baseline in pulse pressure. ABPM ambulatory blood pressure monitoring, CANA canagliflozin, CI confidence interval, LS least squares, PBO placebo, SE standard errorBack to article page